LPKF Laser: A 29% Correction from the Peak Sets Up a LIDE Order Cliffhanger
29.06.2026 - 04:43:20 | boerse-global.de
The optical equipment maker’s shares closed at €21.60 on Friday, capping a brutal week that erased 24.48% of their value. The sell-off, which handed the stock a seven-day loss of nearly a quarter, represents a dramatic reversal from the euphoria that followed LPKF’s promotion to the SDAX index just days earlier. At €30.20 on June 22, the stock had punched a fresh 52-week high — a level that proved irresistible for profit-takers.
By the close, the share price had slid almost 29% from that peak, leaving market participants to sift through the wreckage of a rally that still shows a year-to-date gain of roughly 259%. The annualized volatility of 136% underscores just how jittery trading has become, while the relative strength index at 46.2 sits in neutral territory — neither overheated nor deeply oversold.
The LIDE Vortex
At the heart of the feverish price action lies the LIDE process, a glass-processing technology that LPKF sees as critical for next-generation chip packaging. The company has been testing the system at multiple semiconductor customers, and Tuesday, June 30, is widely viewed as a milestone for news flow. The management signalled in June that it is in concrete discussions with clients and expects the first high-volume orders to land before the end of the year.
Yet LPKF has been careful not to include any potential LIDE volume orders in its 2026 financial guidance. That caution reflects a key reality: even if the technology passes customer validation, the real production ramp-up is unlikely before 2027 because downstream qualification steps remain outside the company’s direct control. For a stock that derived much of its year-to-date surge from LIDE-induced hype, any delay in commercial visibility triggers above-average selling pressure.
Should investors sell immediately? Or is it worth buying LPKF Laser?
Operational Realities Beneath the Hype
LPKF’s first-quarter results offer a sobering counterpoint to the equity market’s dreams. Revenue slid to €17.1 million from €25.3 million a year earlier, dragged down by a weak solar division. The EBIT printed a loss of €6.9 million. That made the subsequent rally all the more striking — and explains why some investors felt compelled to bank profits.
On the plus side, order intake climbed to €24.1 million, pushing the book-to-bill ratio to a solid 1.4. The gap between new orders and recognized revenue suggests a recovery in demand is taking shape, but it has yet to translate into reported sales. The restructuring programme dubbed “North Star” is expected to tighten the cost base further, though at a price: charges of 3–4% of revenue will weigh on the income statement in 2026.
What’s Next
The next official catalyst arrives on July 23, when LPKF publishes its half-year report. Until then, the corporate calendar is thin — the company is attending a medical technology fair in Ulm on July 1–2, an industry event rather than a capital-market catalyst. For the full year, management forecasts group revenue of €105–€120 million and an adjusted EBIT margin between –3.0% and +4.5%, a wide range that leaves plenty of room for both disappointment and surprise.
LPKF Laser at a turning point? This analysis reveals what investors need to know now.
Investors now face a classic dilemma: a stock that has given back nearly a third of its rally in two weeks, versus a technology with genuine long-term promise that still lacks a binding commercial launch. Tuesday’s LIDE deadline may provide some clarity. Or it may simply extend the waiting game.
Ad
LPKF Laser Stock: New Analysis - 29 June
Fresh LPKF Laser information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
